Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma.
Diagnostic values of serum cathepsin B and D in patients with nasopharyngeal carcinoma.
复制标题
血清组织蛋白酶B、D对鼻咽癌的诊断价值
DOI：
10.1186/s12885-016-2283-4
复制
发表时间：
2016-03-19
期刊：
影响因子：
3.8
通讯作者：
Tang F
中科院分区：
文献类型：
--
作者：
Tan G;Liu Q;Tang X;Kang T;Li Y;Lu J;Zhao X;Tang F
探讨肿瘤患者血清组织蛋白酶B （CTSB）和组织蛋白酶D （CTSD）浓度升高对某些肿瘤类型的诊断和预后意义。在鼻咽癌活检组织中检测到CTSD和CTSB的高表达。然而，CTSD和CTSB是否可以作为鼻咽癌的诊断和预后指标尚不清楚。该研究收集了40名健康志愿者和80名NPC患者的血清样本。采用酶联免疫吸附法（ELISA）检测血清中CTSB和CTSD的含量。同时，评估CTSB和CTSD浓度与临床病理预后的关系。本文对80例鼻咽癌患者进行了两项指标诊断鼻咽癌的敏感性和特异性评价。ELISA分析显示，鼻咽癌患者血清中CTSB浓度为12.5±3.5 mg/L（中位数为12.4 mg/L）， CTSD浓度为15.7±8.7 mg/L（中位数为14.7 mg/L）。鼻咽癌患者的CTSB和CTSD水平明显高于健康对照人群（p = 0.001; p = 0.001）。鼻咽癌患者血清中CTSB和CTSD的存在与肿瘤淋巴结转移（TNM）评分相关（p = 0.001）。其他参数不确定是重要的。受试者工作特征（ROC）分析显示，CTSB截断浓度为12.4 mg/L时，预测无进展生存期的敏感性为61.9%，特异性为63.2%(曲线下面积(AUC) = 0.525；95% ci, 39.7-65.2；p = 0.704)；而CTSD截断浓度为14.7 mg/L时，敏感性为66.7%，特异性为58.5% （AUC = 0.552; 95% CI, 42.3-68.1; p = 0.42）。血清CTSB和CTSD浓度对鼻咽癌有诊断价值。然而，血清CTSB和CTSD水平对鼻咽癌患者的预后没有影响。
The diagnostic and prognostic significance of increased cathepsin B (CTSB) and cathepsin D (CTSD) concentration in the serum of cancer patients were evaluated for some tumor types. High expression of CTSD and CTSB was detected in biopsy tissues from nasopharyngeal carcinoma (NPC). However, whether CTSD and CTSB serve as diagnostic and prognostic markers of NPC remains unclear. Serum samples were collected from 40 healthy volunteers and 80 NPC patients enrolled in the study. CTSB and CTSD in the serum samples were detected using enzyme-linked immunosorbent assay (ELISA). Concomitantly, the relationship between CTSB and CTSD concentrations and clinicopathological prognosis was assessed. The sensitivity and specificity of the two components in the diagnosis of NPC were evaluated in 80 NPC patients. ELISA analysis showed that in the sera obtained from NPC patients, the CTSB concentration was 12.5 ± 3.5 mg/L (median, 12.4 mg/L), and the CTSD concentration was 15.7 ± 8.7 mg/L (median, 14.7 mg/L). CTSB and CTSD levels were significantly higher in the NPC patient population compared to the healthy control population (p = 0.001; p = 0.001, respectively). The presence of CTSB and CTSD in the serum of the patients with NPC correlated with the tumor node metastasis (TNM) scores (p = 0.001). Other parameters were not identified to be of significance. Receiver operating characteristic (ROC) analysis showed that a cut off CTSB concentration of 12.4 mg/L had 61.9 % sensitivity and 63.2 % specificity in the prediction of progression-free survival (Area under the curve (AUC) = 0.525; 95 % CI, 39.7–65.2; p = 0.704); whereas a cut off CTSD concentration of 14.7 mg/L had 66.7 % sensitivity, and 58.5 % specificity (AUC = 0.552; 95 % CI, 42.3–68.1; p = 0.42). Serum CTSB and CTSD concentrations were found to have a diagnostic value in NPC. However, the CTSB and CTSD serum levels had no prognostic role for the outcome in NPC patients.